

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
29 August 2019 (29.08.2019)



(10) International Publication Number
WO 2019/162306 A1

(51) International Patent Classification:

C07D 209/10 (2006.01) A61P 25/18 (2006.01)
C07D 235/10 (2006.01) A61P 25/24 (2006.01)
A61P 25/00 (2006.01) A61P 25/28 (2006.01)
A61P 25/16 (2006.01) A61K 31/496 (2006.01)

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2019/054171

(22) International Filing Date:

20 February 2019 (20.02.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

18461519.3 21 February 2018 (21.02.2018) EP

(71) Applicant: **ADAMED PHARMA S.A.** [PL/PL]; ul. Mariana Adamkiewicza 6A, Pienkow, 05-152 Czosnow (PL).

(72) Inventors: **KOLACZKOWSKI, Marcin**; Ul. Lany 2, 32-020 Wieliczka (PL). **BUCKI, Adam**; Przebieczany 558c, 32-020 Przebieczany (PL). **SNIECIKOWSKA, Joanna**; Ul. Długa 22c/1, 32-020 Wieliczka (PL). **MARCINKOWSKA, Monika**; Ul. Na mostkach 3, 31-267 Krakow (PL).

(74) Agent: **SULIKOWSKI, Daniel**; ADMARKA SP. Z O.O., ul. Mariana Adamkiewicza 6, Pienkow, 05-152 Czosnow (PL).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

Declarations under Rule 4.17:


- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))



WO 2019/162306 A1



(54) Title: INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT2A AND 5-HT6 RECEPTOR ANTAGONISTS

(57) Abstract: The invention relates to new 4-(piperazin-1-yl)-2-(trifluoromethyl)-1H-indoles and 4-(piperazin-1-yl)-2-(trifluoromethyl)-1H-benzimidazoles represented by formula (I), wherein all symbols and variables are as defined in the description. The compounds can find use in a method of prevention and/or treatment of diseases selected from the group consisting of Alzheimer's disease, Parkinson's disease, Levy body dementia, dementia-related psychosis, schizophrenia, delusional syndromes and other psychotic conditions related and not related to taking psychoactive substances, depression, anxiety disorders of various aetiology, sleep disorders of various aetiology.